Malaysia Biotech Industry Lags In Expected Growth
This article was originally published in PharmAsia News
Executive Summary
Malaysia's experiment in building a biotechnology industry is lagging behind initial goals as the government approaches the second five-year phase set to begin in 2011. Plans call for the biotech industry to more than double its share of the economy to 2.5 percent within the 2011-2016 period. Since the National Biotechnology Policy was adopted in 2005, the biotech industry has grown only enough to constitute 1 percent of gross domestic product. The head of the government's Malaysia Biotechnology Corp said the nation needs more cooperation between researchers and industry players. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.